MA27389A1 - Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. - Google Patents
Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.Info
- Publication number
- MA27389A1 MA27389A1 MA28124A MA28124A MA27389A1 MA 27389 A1 MA27389 A1 MA 27389A1 MA 28124 A MA28124 A MA 28124A MA 28124 A MA28124 A MA 28124A MA 27389 A1 MA27389 A1 MA 27389A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- formula
- benzimidazole derivatives
- derivatives useful
- antiproliferative agents
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. Mandataire SANTABELLI REVENDICATION DE PRIORITES US 28 Août 2002 60/406,524 US 8 Octobre 2002 60/417,047 Dérivés de benzimidazole nouveaux utiles comme agents antiproliferatifs La présente invention concerne des composés de formule (1] et leurs sels, précurseurs médicamenteux et produits de solvatation pharmaceutiquement acceptables, formule dans laquelle R1, R2, R3 et R4 répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des méthodes pour le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères en administrant les composés de formule (1), et des compositions pharmaceutiques pour le traitement de telles affections, qui contiennent les composés de formule (1). La présente invention concerne également des procédés pour la préparation des composés de formule (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40652402P | 2002-08-28 | 2002-08-28 | |
| US41704702P | 2002-10-08 | 2002-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27389A1 true MA27389A1 (fr) | 2005-06-01 |
Family
ID=31981411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28124A MA27389A1 (fr) | 2002-08-28 | 2005-02-28 | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US7071337B2 (fr) |
| EP (1) | EP1594858B1 (fr) |
| JP (1) | JP4551771B2 (fr) |
| KR (2) | KR20070086768A (fr) |
| CN (1) | CN1319966C (fr) |
| AP (1) | AP2005003237A0 (fr) |
| AR (1) | AR041055A1 (fr) |
| AT (1) | ATE445610T1 (fr) |
| AU (1) | AU2003250499B2 (fr) |
| BR (1) | BRPI0313942C1 (fr) |
| CA (1) | CA2495577C (fr) |
| CR (1) | CR7698A (fr) |
| CU (1) | CU23413B7 (fr) |
| CY (1) | CY1110580T1 (fr) |
| DE (1) | DE60329715D1 (fr) |
| DK (1) | DK1594858T3 (fr) |
| DO (1) | DOP2003000694A (fr) |
| EA (1) | EA008448B1 (fr) |
| EC (1) | ECSP055633A (fr) |
| ES (1) | ES2333219T3 (fr) |
| GE (1) | GEP20064005B (fr) |
| HN (1) | HN2003000257A (fr) |
| HR (1) | HRP20050191B1 (fr) |
| IL (1) | IL166832A (fr) |
| IS (1) | IS2738B (fr) |
| MA (1) | MA27389A1 (fr) |
| MX (1) | MXPA05001256A (fr) |
| MY (1) | MY139357A (fr) |
| NO (1) | NO20051303L (fr) |
| NZ (1) | NZ538427A (fr) |
| OA (1) | OA12916A (fr) |
| PA (1) | PA8580301A1 (fr) |
| PE (1) | PE20050131A1 (fr) |
| PL (1) | PL377678A1 (fr) |
| PT (1) | PT1594858E (fr) |
| RS (1) | RS20050180A (fr) |
| SI (1) | SI1594858T1 (fr) |
| TW (1) | TW200407131A (fr) |
| UY (1) | UY27952A1 (fr) |
| WO (1) | WO2004020431A2 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1641780T3 (da) * | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| CA2582479C (fr) * | 2004-10-07 | 2011-07-12 | Pfizer Products Inc. | Derives de benzoimidazole utiles en tant qu'agents antiproliferatifs |
| EP1877444A2 (fr) | 2005-04-26 | 2008-01-16 | Pfizer, Inc. | Anticorps de la p-cadherine |
| SI2447283T1 (sl) | 2005-09-07 | 2015-12-31 | Amgen Fremont Inc. | Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1 (ALK-1) |
| EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
| UA101611C2 (ru) | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
| SI2300455T1 (sl) | 2008-05-21 | 2017-12-29 | Incyte Holdings Corporation | Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| JP6039559B2 (ja) | 2010-09-02 | 2016-12-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体 |
| GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
| JP6407504B2 (ja) * | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| US11642340B2 (en) | 2012-09-26 | 2023-05-09 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| PL3212629T3 (pl) * | 2014-10-31 | 2019-05-31 | Genoscience Pharma Sas | Podstawione 2,4-diamino-chinoliny jako nowe środki przeciwnowotworowe |
| GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| DK3452465T3 (da) | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| US12662706B2 (en) | 2016-11-02 | 2026-06-23 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| KR20180074792A (ko) | 2016-11-02 | 2018-07-03 | 아로그 파마슈티칼스, 인코퍼레이티드 | 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙 |
| CN107382983B (zh) * | 2017-08-24 | 2020-08-07 | 扬州市三药制药有限公司 | 一种治疗白血病药物的合成方法 |
| CN107382984B (zh) * | 2017-08-24 | 2020-07-10 | 扬州市三药制药有限公司 | 一种治疗白血病药物的制备方法 |
| CN110840893A (zh) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN117447376B (zh) * | 2019-12-09 | 2026-06-09 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
| CN114981298B (zh) | 2019-12-12 | 2024-08-20 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| WO2022019998A1 (fr) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Formes cristallines de crénolanib et leurs procédés d'utilisation |
| AU2021320860A1 (en) * | 2020-08-05 | 2023-02-23 | The General Hospital Corporation | Salt inducible kinase inhibitors |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| WO2022090547A1 (fr) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production de caroténoïdes par fermentation |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
| CN113683594B (zh) * | 2021-09-07 | 2022-12-27 | 曲靖师范学院 | 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用 |
| JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| US20250129067A1 (en) | 2021-11-08 | 2025-04-24 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| CN114409632B (zh) * | 2022-02-22 | 2024-04-30 | 北京鲲达宇科技有限公司 | 2-取代氨基-3-苯并咪唑取代的喹啉衍生物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| CA2393026A1 (fr) * | 1999-11-30 | 2001-06-07 | Paul A. Wender | Analogues de la bryostatine, methodes de synthese et utilisations |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| JP2008002005A (ja) * | 2006-06-21 | 2008-01-10 | Shimada Shoji Kk | 衣服用パッド |
-
2003
- 2003-08-12 PA PA8580301A patent/PA8580301A1/es unknown
- 2003-08-14 WO PCT/IB2003/003634 patent/WO2004020431A2/fr not_active Ceased
- 2003-08-14 NZ NZ538427A patent/NZ538427A/en not_active IP Right Cessation
- 2003-08-14 DE DE60329715T patent/DE60329715D1/de not_active Expired - Lifetime
- 2003-08-14 MX MXPA05001256A patent/MXPA05001256A/es active IP Right Grant
- 2003-08-14 PL PL37767803A patent/PL377678A1/pl not_active Application Discontinuation
- 2003-08-14 EA EA200500174A patent/EA008448B1/ru not_active IP Right Cessation
- 2003-08-14 JP JP2004569727A patent/JP4551771B2/ja not_active Expired - Lifetime
- 2003-08-14 CA CA 2495577 patent/CA2495577C/fr not_active Expired - Lifetime
- 2003-08-14 BR BRPI0313942A patent/BRPI0313942C1/pt not_active IP Right Cessation
- 2003-08-14 GE GEAU2003008665 patent/GEP20064005B/en unknown
- 2003-08-14 AP AP2005003237A patent/AP2005003237A0/xx unknown
- 2003-08-14 KR KR1020077014809A patent/KR20070086768A/ko not_active Ceased
- 2003-08-14 SI SI200331687T patent/SI1594858T1/sl unknown
- 2003-08-14 AT AT03791110T patent/ATE445610T1/de active
- 2003-08-14 HR HRP20050191AA patent/HRP20050191B1/hr not_active IP Right Cessation
- 2003-08-14 OA OA1200500059A patent/OA12916A/en unknown
- 2003-08-14 EP EP20030791110 patent/EP1594858B1/fr not_active Expired - Lifetime
- 2003-08-14 CN CNB038206218A patent/CN1319966C/zh not_active Expired - Lifetime
- 2003-08-14 AU AU2003250499A patent/AU2003250499B2/en not_active Ceased
- 2003-08-14 KR KR20057003493A patent/KR100816166B1/ko not_active Expired - Fee Related
- 2003-08-14 PT PT03791110T patent/PT1594858E/pt unknown
- 2003-08-14 DK DK03791110T patent/DK1594858T3/da active
- 2003-08-14 ES ES03791110T patent/ES2333219T3/es not_active Expired - Lifetime
- 2003-08-19 DO DO2003000694A patent/DOP2003000694A/es unknown
- 2003-08-25 HN HN2003000257A patent/HN2003000257A/es unknown
- 2003-08-25 PE PE2003000864A patent/PE20050131A1/es active IP Right Grant
- 2003-08-26 UY UY27952A patent/UY27952A1/es not_active Application Discontinuation
- 2003-08-26 US US10/648,151 patent/US7071337B2/en not_active Expired - Lifetime
- 2003-08-26 AR ARP030103073 patent/AR041055A1/es unknown
- 2003-08-26 MY MYPI20033225 patent/MY139357A/en unknown
- 2003-08-27 TW TW92123585A patent/TW200407131A/zh unknown
-
2005
- 2005-01-20 IS IS7660A patent/IS2738B/is unknown
- 2005-02-10 IL IL166832A patent/IL166832A/en active IP Right Grant
- 2005-02-14 CU CU20050031A patent/CU23413B7/es not_active IP Right Cessation
- 2005-02-22 CR CR7698A patent/CR7698A/es unknown
- 2005-02-28 EC ECSP055633 patent/ECSP055633A/es unknown
- 2005-02-28 MA MA28124A patent/MA27389A1/fr unknown
- 2005-03-14 NO NO20051303A patent/NO20051303L/no not_active Application Discontinuation
- 2005-08-14 RS YUP-2005/0180A patent/RS20050180A/sr unknown
-
2009
- 2009-11-30 CY CY20091101249T patent/CY1110580T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57539B1 (fr) | Inhibiteurs à petites molécules de mutant de kras g12c | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| EP1328269B2 (fr) | Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| MA29926B1 (fr) | Derives de pyrazine | |
| CA2153340C (fr) | Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA31466B1 (fr) | Derives de benzimidazole | |
| MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| TNSN05298A1 (fr) | Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| MA27009A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
| TNSN05250A1 (fr) | Pyrimidinones substituees | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| TNSN08139A1 (fr) | Composes therapeutiques | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| MA27095A1 (fr) | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer | |
| MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA26956A1 (fr) | Pyrimidine-2,4,6,triones inhibitrices de metalloproteinases. | |
| MA27142A1 (fr) | Derives de piperazine a activite antagoniste des recepteurs ccr1 |